Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Symphogen's Sym004 Phase 1 data on advanced solid tumors to be presented at ASCO 2011

Symphogen announced today that the company will present preliminary Phase 1 data evaluating the company's lead cancer compound, Sym004, at the 2011 Annual Meeting of the American Society of Clinical Oncology in Chicago.

1 Jun 2011

CTI regains compliance with all applicable NASDAQ listing standards

Cell Therapeutics, Inc. announced that it has received a letter from The NASDAQ Stock Market LLC, indicating that CTI has regained compliance with the minimum bid price rule (i.e., NASDAQ Listing Rule 5550(a)(2)) for continued listing on The NASDAQ Capital Market and that CTI is in compliance with all applicable listing standards.

1 Jun 2011

Non-invasive trigeminal nerve stimulation shows promise for drug-resistant epilepsy

Medications are the mainstay of treatment for epilepsy, but for a considerable number of patients — estimated to be as many as 1 million in the U.S. — drugs don't work. These patients suffer from a type of epilepsy known as refractory or drug-resistant epilepsy, in which drugs can't control their seizures.

1 Jun 2011

SGO's Clinical Document outlines expert recommendations for gynecologic cancer surveillance

Although gynecologic cancers account for only 10 percent of all new cancer cases in women, these cancers account for 20 percent of all female cancer survivors. Because long-term survival is now more common, it is increasingly important to detect recurrence.

1 Jun 2011

New genetic test can predict clinical outcomes in glioblastoma patients

New research proves that a change in a particular gene can identify which patients with a specific kind of brain cancer will respond better to treatment. Testing for the gene can distinguish patients with a more- or less-aggressive form of glioblastoma, the most common and an often-fatal type of primary brain cancer, and help guide therapy, the researchers say.

1 Jun 2011

Lymphoma vaccine extends disease-free survival by 14 months

A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better response for patients with a specific biological marker, a team led by scientists at The University of Texas MD Anderson Cancer Center reported today in the online version of Journal of Clinical Oncology.

1 Jun 2011

Patrick K. Donnelly announces official launch of Aptiv Solutions

Chairman and CEO Patrick K. Donnelly today announced the official launch of Aptiv Solutions, a global biopharmaceutical and medical device development services company.

1 Jun 2011

Women with ovarian cancer could benefit from new targeted testing

Women with ovarian cancer could be helped by a new test that identifies the specific type of tumour they have, a conference will hear this week.

1 Jun 2011

FDA approves APP Pharmaceuticals' Piperacillin and Tazobactam for Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Piperacillin and Tazobactam for Injection, the number one prescribed intravenous antibiotic in the U.S. APP will launch the product immediately.

1 Jun 2011

IPSOGEN announces two studies on Genomic Grade test to be presented at ASCO 2011

IPSOGEN SA today announces that two studies on the Genomic Grade test will be presented at the American Society for Clinical Oncology Annual Meeting, that will take place June 3-7, 2011, in Chicago, Ill, USA.

1 Jun 2011

Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

AVEO Pharmaceuticals, Inc. today announced it has entered into an exclusive license agreement with Centocor Ortho Biotech Inc. for the worldwide development and commercialization of AVEO's internally-discovered antibodies targeting the RON receptor.

1 Jun 2011

Cell phones and cancer – link established

In its latest announcement the World Health Organization (WHO) said that radiation from cell phones can possibly cause cancer. According to the WHO's International Agency for Research on Cancer (IARC), radiofrequency electromagnetic fields have been classified as possibly carcinogenic to humans (group 2B) on the basis of an increased risk for glioma that some studies have associated with the use of wireless phones.

1 Jun 2011

Latest Breast cancer screening guidelines deemed unsafe by 80% women

Nearly 80 percent of women feel the new guidelines against breast cancer are unsafe as they stated that screening for those under 50 is not mandatory. The controversy over screening mammography flared up in late 2009, when a government-funded group of independent experts decided to change its recommendations. Instead of advising annual mammograms in all women age 40 and above, the U.S. Preventive Services Task Force (USPSTF) said women shouldn't routinely get screened until they hit 50, and those between 50 and 74 should only have mammograms every two years. But most of the women also seriously overestimate their risk of developing the disease, researchers from the University of Massachusetts Medical School in Worcester found.

31 May 2011

Enrollment complete in BioSante's LibiGel Phase III cardiovascular and breast cancer safety study

BioSante Pharmaceuticals, Inc., today announced completion of enrollment in its ongoing LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.

31 May 2011

Defiante, Dyax expand KALBITOR partnership to treat hereditary angioedema

Dyax Corp. and Defiante Farmaceutica S.A., an affiliate of the pharmaceutical group Sigma-Tau, announced today an expansion of their strategic partnership for KALBITOR in the treatment of hereditary angioedema and other therapeutic indications to include development and commercialization rights in Latin America, excluding Mexico and the Caribbean, Taiwan, Singapore and South Korea.

31 May 2011

YM announces updates on nimotuzumab clinical development program

YM BioSciences Inc., today provided an update on the development program for nimotuzumab, including its North American clinical program for nimotuzumab, manufacturing scale-up activities, and data presentations anticipated for nimotuzumab at the 2011 Annual Meeting of the American Society of Clinical Oncology.

31 May 2011

BioAlliance's appeals in SpePharm litigation rejected

SpePharm Holding B.V. announces that the appeals lodged by BioAlliance Pharma S.A. - a French company listed on Paris Euronext - before the Paris Court of Appeals have been rejected.

31 May 2011

Heptares, AstraZeneca partner to discover and develop new GPCR drug targets

AstraZeneca and Heptares Therapeutics today announced they have entered a four-year collaboration focused on the potential discovery and development of new medicines targeting G-protein coupled receptors.

31 May 2011

EpiCept completes $10.6 million 11.5% senior secured term loan facility with MidCap Financial

EpiCept Corporation today announced that it has completed a $10.6 million 11.5% senior secured term loan facility with MidCap Financial LLC.

31 May 2011

Positive results from DavosLife Natural e3 phase I clinical trial in resectable pancreatic cancer

Davos Life Science has today announced preliminary results of a phase I clinical trial of its Natural e3 delta-tocotrienol (Natural e3) in patients with resectable pancreatic cancer. Tocotrienols are highly potent members of the Vitamin E family that have been found by researchers to inhibit the growth and survival of various types of cancer cells.

30 May 2011

Oncology News and Research

Further Reading

Symphogen's Sym004 Phase 1 data on advanced solid tumors to be presented at ASCO 2011

CTI regains compliance with all applicable NASDAQ listing standards

Non-invasive trigeminal nerve stimulation shows promise for drug-resistant epilepsy

SGO's Clinical Document outlines expert recommendations for gynecologic cancer surveillance

New genetic test can predict clinical outcomes in glioblastoma patients

Lymphoma vaccine extends disease-free survival by 14 months

Patrick K. Donnelly announces official launch of Aptiv Solutions

Women with ovarian cancer could benefit from new targeted testing

FDA approves APP Pharmaceuticals' Piperacillin and Tazobactam for Injection

IPSOGEN announces two studies on Genomic Grade test to be presented at ASCO 2011

Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

Cell phones and cancer – link established

Latest Breast cancer screening guidelines deemed unsafe by 80% women

Enrollment complete in BioSante's LibiGel Phase III cardiovascular and breast cancer safety study

Defiante, Dyax expand KALBITOR partnership to treat hereditary angioedema

YM announces updates on nimotuzumab clinical development program

BioAlliance's appeals in SpePharm litigation rejected

Heptares, AstraZeneca partner to discover and develop new GPCR drug targets

EpiCept completes $10.6 million 11.5% senior secured term loan facility with MidCap Financial

Positive results from DavosLife Natural e3 phase I clinical trial in resectable pancreatic cancer

Event guide: 10th CAR-TCR Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News